Log in to search using one of your social media accounts:


Versartis ’ Phase III trial of somavaratan fails to meet endpoint for GHD

US-based biopharmaceutical firm Versartis has reported results from a Phase III clinical trial (VELOCITY) of somavaratan (VRS-317) to treat paediatric patients with growth hormone deficiency (GHD).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news

Related Links:

More News: Clinical Trials | Hormones | Pediatrics | Pharmaceuticals